Information  X 
Enter a valid email address

VASTox plc (SUMM)

  Print      Mail a friend

Friday 07 October, 2005

VASTox plc

New Board Appointment

VASTox plc
07 October 2005


For immediate release                                             7 October 2005

                                   VASTox plc
                          ('VASTox' or 'the Company')

                   Sir Brian Richards CBE joins VASTox Board


Oxford, UK: 7 October 2005 - VASTox plc (AIM: VOX), the drug discovery and
services business specialising in chemical genomics, is pleased to announce
today that Sir Brian Richards CBE has been appointed to the Board of VASTox as a
Non-Executive Director.

Sir Brian Richards, aged 73, has a wealth of experience in European biotech and
pharmaceutical companies and, following 13 years in academia and work with the
Medical Research Council, he became Vice President for Research and Development
for G.D. Searle at High Wycombe (1966-86). In 1986 he co-founded British
Biotechnology Ltd and served as Executive Chairman until 1994.

In 1990 he was awarded the CBE and in 1997 was Knighted.  Both awards were in
recognition for services to the biotechnology industry.

He is currently Chairman of Alizyme plc, Cozart plc, MAN Mail (Guernsey) Ltd and
Lipoxen Ltd.  Previously he has held Non-Executive Chairmanships or
Directorships in several biopharmaceutical companies including Peptide
Therapeutics (later Acambis plc), Oxford Biomedica plc and CeNeS Ltd.

In accordance with paragraph (g) of Schedule 2 of the AIM Rules, there are no
other matters be announced with respect to Sir Brian Richards.

Sir Brian Richards commented: 'I am pleased to accept a position on the Board of
VASTox.  The Company has a unique business model and I believe is well placed to
exploit the emerging market for chemical genomics technologies.  I am excited to
be working with such an ambitious team.'

Professor Stephen Davies, Chairman of VASTox, said: 'I am delighted that Sir
Brian Richards has agreed to join VASTox as an integral member of our Board.
Aside from being a successful entrepreneur, Sir Brian has a formidable breadth
of expertise in building value in the biotech industry, having been a pioneer in
the sector for many years.  My fellow directors and I look forward to working
with Sir Brian as we accelerate VASTox through the next stage of our corporate
development.'

The Company also reports that it will announce interim results for the six
months to 31 July 2005 on 12 October 2005.


For more information please contact:

VASTox plc
Steven Lee, Chief Executive Officer                                01235 443 901
                                                                   07766 913 898
Buchanan Communications
Tim Anderson / Mark Court / Mary-Jane Johnson                      020 7466 5000


Notes for Editors:


About VASTox plc

VASTox is a chemical genomics technology company that provides services to the
pharmaceutical industry and discovers and develops proprietary novel drugs. The
company's technology platform aims to use high volume, high content screening
using zebrafish and fruitflies to provide a high level of predictability of the
efficacy and toxicity of potential drug compounds in humans which has the
potential to dramatically decrease the time and cost of drug discovery and
development. VASTox was formed in January 2003, from the University of Oxford,
by some of the UK's foremost scientists who have taken a highly creative
approach to the problems involved in drug discovery and who have a proven record
in delivering technological excellence. The company listed on the London Stock
Exchange AIM in October 2004.


                      This information is provided by RNS
            The company news service from the London Stock Exchange